Get started
Author

Lynn De Mey

Observed names: De Mey Lynn, De Mey, Lynn
ORCID: 0000-0002-1361-6344
Observed ORCID: 0000-0002-1361-6344
OpenAlex ID: A5040098266
Current status and future expectations of nanobodies in oncology trials
2023 · Tessa De Pauw, Lynn De Mey, et al. · Expert Opinion on Investigational Drugs · 38
PDF
Advancements in nuclear imaging using radiolabeled nanobody tracers to support cancer immunotherapy
2024 · Katty Zeven, Yoline Lauwers, et al. · Immunotherapy Advances · 17
PDF
Durvalumab-induced thyroiditis in a patient with non-small cell lung carcinoma: a case report and review of pathogenic mechanisms
2022 · Jeroen M. K. de Filette, Stéphanie André, et al. · BMC Endocrine Disorders · 8
PDF
Radiation-Induced Side Effects to the Skin Due to 177Lu-PSMA Extravasation
2026 · Heather Corveleyn, Lynn De Mey, et al. · Clinical Nuclear Medicine · 1
Macrophage Spatial Polarity to T Cells Predicts Prognosis in Young Women with Luminal Breast Cancer
2026 · Artur Mezheyeuski, Garazi Serna, et al. · SSRN Electronic Journal
18F-FDG PET/CT in Waldenström associated amyloidosis.
2023 · Lynn De Mey, Sim Vermeulen, et al. · PubMed
PDF
The course and outcome of subacute thyroiditis: a retrospective analysis and predictive model
2022 · Jeroen de Filette, Lynn De Mey, et al. · Endocrine Abstracts
HLA-DR4/DR13 in a patient with durvalumab-induced thyroiditis
2021 · de Filette, Jeroen M.K, et al. · Endocrine Abstracts
Works count: 11
Citation count: 64
H-index: 3
I10-index: 2
Year
Topic
Type